Seelos Therapeutics, Inc. (SEEL)

0.3010 -0.0261 (-7.98%) At close: 04:00PM EDT

Seelos Therapeutics, Inc.

300 Park Avenue
2nd Floor
New York, NY 10022
United States
646 293 2100
https://seelostherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 15

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Raj Mehra J.D., Ph.D.	Founder, Chairman, CEO & President	599.53k	N/A	1961
Mr. Michael J. Golembiewski	Chief Financial Officer	388.2k	N/A	1972
Ms. Kimberly Farrand	Senior Director of Clinical Development & Operations	N/A	N/A	N/A
Mr. Anthony Marciano	Chief Communications Officer	N/A	N/A	N/A
Gopal Krishna Ph.D.	Head of Manufacturing & Technical Operations	N/A	N/A	N/A
Tim Whitaker M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Karen Fusaro	Senior VP & Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Corporate Governance

Seelos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.